342 related articles for article (PubMed ID: 24508951)
1. Omalizumab management beyond clinical trials: the added value of a network model.
Caminati M; Senna G; Chieco Bianchi F; Marchi MR; Vianello A; Micheletto C; Pomari C; Tognella S; Savoia F; Mirisola V; Rossi A;
Pulm Pharmacol Ther; 2014 Oct; 29(1):74-9. PubMed ID: 24508951
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab for severe allergic asthma in clinical trials and real-life studies: what we know and what we should address.
Caminati M; Senna G; Guerriero M; Dama AR; Chieco-Bianchi F; Stefanizzi G; Montagni M; Ridolo E
Pulm Pharmacol Ther; 2015 Apr; 31():28-35. PubMed ID: 25640019
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of omalizumab on pulmonary function in patients with allergic asthma with and without chronic rhinosinusitis.
Clavenna MJ; Turner JH; Samuelson M; Tanner SB; Duncavage J; Chandra RK
Allergy Asthma Proc; 2016; 37(1):23-6. PubMed ID: 26831843
[TBL] [Abstract][Full Text] [Related]
4. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
[TBL] [Abstract][Full Text] [Related]
5. Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy.
Novelli F; Latorre M; Vergura L; Caiaffa MF; Camiciottoli G; Guarnieri G; Matucci A; Macchia L; Vianello A; Vultaggio A; Celi A; Cazzola M; Paggiaro P;
Pulm Pharmacol Ther; 2015 Apr; 31():123-9. PubMed ID: 25281265
[TBL] [Abstract][Full Text] [Related]
6. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
[TBL] [Abstract][Full Text] [Related]
7. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
8. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
9. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
10. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results.
Zazzali JL; Raimundo KP; Trzaskoma B; Rosén KE; Schatz M
Allergy Asthma Proc; 2015; 36(4):283-92. PubMed ID: 26108086
[TBL] [Abstract][Full Text] [Related]
11. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
12. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
Shitrit D; Talker O; Metabichek A; Yaakovi I
Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
Chen HC; Huang CD; Chang E; Kuo HP
BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
[TBL] [Abstract][Full Text] [Related]
15. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
[TBL] [Abstract][Full Text] [Related]
17. Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience.
Caminati M; Senna G; Stefanizzi G; Bellamoli R; Longhi S; Chieco-Bianchi F; Guarnieri G; Tognella S; Olivieri M; Micheletto C; Festi G; Bertocco E; Mazza M; Rossi A; Vianello A;
BMC Pulm Med; 2016 Aug; 16(1):128. PubMed ID: 27562427
[TBL] [Abstract][Full Text] [Related]
18. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
